Dianthus Therapeutics, Inc.

Symbol: DNTH

NASDAQ

26.69

USD

Market price today

  • -5.9855

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 783.27M

    MRK Cap

  • 0.00%

    DIV Yield

Dianthus Therapeutics, Inc. (DNTH) Financial Statements

On the chart you can see the default numbers in dynamics for Dianthus Therapeutics, Inc. (DNTH). Companys revenue shows the average of 1.34 M which is 0.348 % gowth. The average gross profit for the whole period is 0.547 M which is 1.571 %. The average gross profit ratio is 0.185 %. The net income growth for the company last year performance is 0.530 % which equals -0.571 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Dianthus Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 1.159. In the realm of current assets, DNTH clocks in at 177.451 in the reporting currency. A significant portion of these assets, precisely 173.718, is held in cash and short-term investments. This segment shows a change of 1.301% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0.066, if any, in the reporting currency. This indicates a difference of 10.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0.168 in the reporting currency. This figure signifies a year_over_year change of -0.258%. Shareholder value, as depicted by the total shareholder equity, is valued at 168.87 in the reporting currency. The year over year change in this aspect is -4.806%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0.478, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

521.17173.775.57.6
148.8
145.7
142.6
51.4
4.5

balance-sheet.row.short-term-investments

118.6241.460.145.3
90.7
80.7
84.2
0
0

balance-sheet.row.net-receivables

1.230.55.61.5
0
0
0
0
6.3

balance-sheet.row.inventory

000.90.3
0
0
0
0
0

balance-sheet.row.other-current-assets

8.593.30.10
2.7
4.1
2.8
1.1
0.1

balance-sheet.row.total-current-assets

530.98177.5829.4
151.5
149.8
145.3
52.5
10.8

balance-sheet.row.property-plant-equipment-net

1.690.810
8.3
9.9
10.2
2
0.5

balance-sheet.row.goodwill

0000
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0

balance-sheet.row.long-term-investments

0.130.10.11.8
1.8
1.8
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0

balance-sheet.row.other-non-current-assets

1.141.10.1-1.8
0
0
1.8
0
0

balance-sheet.row.total-non-current-assets

2.9621.10.1
10.1
11.7
12
2
0.5

balance-sheet.row.other-assets

0000
0
0
0
0
0

balance-sheet.row.total-assets

533.95179.483.19.5
161.6
161.5
157.3
54.5
11.3

balance-sheet.row.account-payables

5.872.61.21.4
3.8
2.8
3.5
0.2
1.7

balance-sheet.row.short-term-debt

0.830.40.30
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.420.20.40
0
0
0
0
0

Deferred Revenue Non Current

1.480.70.80
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-

balance-sheet.row.other-current-liab

25.826.56.64
7.7
11.3
6.9
4
0.6

balance-sheet.row.total-non-current-liabilities

1.910.9119.321.3
6.3
6.2
1.2
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.840.20.80
0
0
0
0
0

balance-sheet.row.total-liab

34.6310.5127.526.7
17.7
20.3
11.7
4.1
2.3

balance-sheet.row.preferred-stock

0179.41180
0
0
0
92.4
17.9

balance-sheet.row.common-stock

0.1500.10.1
0
0
0
0
0

balance-sheet.row.retained-earnings

-1033.96-89.4-45.9-17.4
-254.4
-179.5
-102.7
-45.2
-9.7

balance-sheet.row.accumulated-other-comprehensive-income-loss

0.020-0.20
0
0
-1.1
-0.4
0

balance-sheet.row.other-total-stockholders-equity

1533.178.8-116.40.1
398.3
320.6
249.4
3.5
0.9

balance-sheet.row.total-stockholders-equity

499.31168.9-44.4-17.2
143.9
141.2
145.6
50.3
9

balance-sheet.row.total-liabilities-and-stockholders-equity

533.95179.483.19.5
161.6
161.5
157.3
54.5
11.3

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

499.31168.9-44.4-17.2
143.9
141.2
145.6
50.3
9

balance-sheet.row.total-liabilities-and-total-equity

533.95---
-
-
-
-
-

Total Investments

118.6941.560.145.3
92.5
82.4
84.2
0
0

balance-sheet.row.total-debt

1.250.60.80
0
0
0
0
0

balance-sheet.row.net-debt

-401.29-131.7-14.6-7.6
-58.2
-65.1
-58.3
-51.4
-4.5

Cash Flow Statement

The financial landscape of Dianthus Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.266. The company recently extended its share capital by issuing 0.01, marking a difference of -75.410 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0.66 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 20253000.000 in the reporting currency. This is a shift of -1.339 from the previous year. In the same period, the company recorded 0.35, 0, and -0.38, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 133.95, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

cash-flows.row.net-income

-57.78-43.6-28.5-13.1
-74.9
-76.8
-57.5
-35.5
-9.4

cash-flows.row.depreciation-and-amortization

1.150.40.12
2
1.8
0.9
0.4
0

cash-flows.row.deferred-income-tax

-0.07-0.70-2.8
-12.9
-13.5
0
0
0

cash-flows.row.stock-based-compensation

1.652.91.50.1
9.9
10
10.7
2.3
0.7

cash-flows.row.change-in-working-capital

4.864.9-1.73.1
-1.2
8.8
4.2
1.3
1.6

cash-flows.row.account-receivables

0.275.2-4.20
0
0
0
0
0

cash-flows.row.inventory

004.20
0
0
0
0
0

cash-flows.row.account-payables

0.660.72.34.9
0.9
0.1
2.5
-1.1
1

cash-flows.row.other-working-capital

3.93-1-3.9-1.8
-2.1
8.7
1.7
2.4
0.6

cash-flows.row.other-non-cash-items

13.32-0.8-0.60.8
13.1
12.5
-0.1
9.3
0.6

cash-flows.row.net-cash-provided-by-operating-activities

-36.86000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.35-0.1-0.10
-0.4
-3.1
-7.7
-2.2
-0.1

cash-flows.row.acquisitions-net

00-0.2-1.2
0
0
0
0
0

cash-flows.row.purchases-of-investments

-67.19-57.4-61.7-45.3
-95.7
-144.4
-84
0
0

cash-flows.row.sales-maturities-of-investments

77.7877.8290
85.5
149
0
0
0

cash-flows.row.other-investing-activites

10.0100.2-43.5
0
0
0
-0.1
0

cash-flows.row.net-cash-used-for-investing-activites

20.2520.3-59.80
-10.6
1.5
-91.7
-2.3
-0.1

cash-flows.row.debt-repayment

-31.28-0.400
0
0
0
0
0

cash-flows.row.common-stock-issued

0.0102.989.6
67.7
62.3
93
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
-0.1
-0.2
-0.1

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

133.57133.993.8-74.7
0
0
49.2
71.7
10.8

cash-flows.row.net-cash-used-provided-by-financing-activities

133.57133.696.714.9
67.7
62.3
142.1
71.5
10.7

cash-flows.row.effect-of-forex-changes-on-cash

-42.270-81.868.5
0
0
0
0
0

cash-flows.row.net-change-in-cash

74.71177.85
-6.9
6.7
8.6
46.9
4

cash-flows.row.cash-at-end-of-period

402.54132.315.47.6
58.2
65.1
60.1
51.4
4.5

cash-flows.row.cash-at-beginning-of-period

327.8415.47.62.7
65.1
58.3
51.6
4.5
0.5

cash-flows.row.operating-cash-flow

-36.86-36.9-29.1-9.9
-64
-57.1
-41.9
-22.3
-6.5

cash-flows.row.capital-expenditure

-0.35-0.1-0.10
-0.4
-3.1
-7.7
-2.2
-0.1

cash-flows.row.free-cash-flow

-37.22-37-29.2-9.9
-64.4
-60.2
-49.6
-24.5
-6.7

Income Statement Row

Dianthus Therapeutics, Inc.'s revenue saw a change of -0.560% compared with the previous period. The gross profit of DNTH is reported to be 2.47. The company's operating expenses are 50.65, showing a change of 40.205% from the last year. The expenses for depreciation and amortization are 0.35, which is a 1.415% change from the last accounting period. Operating expenses are reported to be 50.65, which shows a 40.205% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.622% year-over-year growth. The operating income is -48.17, which shows a 0.622% change when compared to the previous year. The change in the net income is 0.530%. The net income for the last year was -43.55.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

income-statement-row.row.total-revenue

1.382.86.41.5
0
0
0
0
0

income-statement-row.row.cost-of-revenue

1.330.40.12
2
1.8
0
0
0

income-statement-row.row.gross-profit

0.052.56.3-0.5
-2
-1.8
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

23.67---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

18.67---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-0.1---
-
-
-
-
-

income-statement-row.row.other-expenses

1.88-0.1-0.10
0
0
0
0
0

income-statement-row.row.operating-expenses

48.3750.636.114.6
76.7
81.1
60
35.7
9.3

income-statement-row.row.cost-and-expenses

49.685136.114.6
78.7
83
60
35.7
9.3

income-statement-row.row.interest-income

5.634.81.10
3.8
0
2.4
0.2
0

income-statement-row.row.interest-expense

0003.6
3.8
0
0
0
0.2

income-statement-row.row.selling-and-marketing-expenses

-0.1---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-10.514.60.10
3.8
6.2
2.4
0.2
-0.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.88-0.1-0.10
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-10.514.60.10
3.8
6.2
2.4
0.2
-0.2

income-statement-row.row.interest-expense

0003.6
3.8
0
0
0
0.2

income-statement-row.row.depreciation-and-amortization

1.150.40.12
2
1.8
0.9
0.4
0

income-statement-row.row.ebitda-caps

-46.97---
-
-
-
-
-

income-statement-row.row.operating-income

-48.3-48.2-29.7-13.1
-78.7
-83
-60
-35.7
-9.3

income-statement-row.row.income-before-tax

-57.78-43.6-28.5-13.1
-74.9
-76.8
-57.5
-35.5
-9.4

income-statement-row.row.income-tax-expense

-0.850-1.3-2
7.5
6.2
2.4
0.2
0

income-statement-row.row.net-income

-57.78-43.6-28.5-13.1
-74.9
-76.8
-57.5
-35.5
-9.4

Frequently Asked Question

What is Dianthus Therapeutics, Inc. (DNTH) total assets?

Dianthus Therapeutics, Inc. (DNTH) total assets is 179405000.000.

What is enterprise annual revenue?

The annual revenue is 1381000.000.

What is firm profit margin?

Firm profit margin is 0.038.

What is company free cash flow?

The free cash flow is -2.512.

What is enterprise net profit margin?

The net profit margin is -41.839.

What is firm total revenue?

The total revenue is -34.974.

What is Dianthus Therapeutics, Inc. (DNTH) net profit (net income)?

The net profit (net income) is -43555000.000.

What is firm total debt?

The total debt is 585000.000.

What is operating expences number?

The operating expences are 50645000.000.

What is company cash figure?

Enretprise cash is 132324999.000.